Dr. Peter Maag is the Chief Executive Officer for XDx, Inc. Dr. Maag has over 20 years of Executive Management experience in the pharmaceutical and diagnostic industry. Prior to joining XDx, Dr. Maag was President Novartis Diagnostics based in Emeryville, CA. He headed the expansion of the unit with growth in global markets in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany and lived in a dynamically growing emerging market as Country President, Korea. At Novartis headquarters in Switzerland, He helped the setup of the Infectious Diseases Franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various Healthcare and High Tech companies in their growth efforts, he holds board and advisory positions at Phoenix, Microsonic Systems, and Cobaltix. Dr. Maag studied pharmaceutical sciences in Heidelberg and London and received his Ph.D. from the University of Berlin, Germany.
Matthew Meyer is the Chief Business Officer for XDx. Mr. Meyer has over 15 years of business development, marketing and commercial legal experience in the domestic and international life sciences industry. Prior to joining XDx, Mr. Meyer was Vice President, Business Development and General Counsel at Cerimon Pharmaceuticals where he led the in-license and partnering of prescription products to treat pain and inflammation. Prior to that, Mr. Meyer held senior management positions at Draeger Medical Systems, the U.S. subsidiary of the German-based global medical device company, most recently serving as Vice President and General Counsel. Prior to Draeger, Mr. Meyer held positions of increasing responsibility at Novartis Pharma AG in Basel, Switzerland, including serving as Head of Global Marketing Channel Innovations, a role in which he helped foster greater marketing and sales effectiveness through the use of innovative technology-based initiatives. Previously, Mr. Meyer was the Vice President, Global Business Development and Legal Affairs at Allscripts’ Physician’s Interactive division, which was a leader in online marketing programs to physicians, and spent five years as a commercial and transactional attorney at Pfizer Inc, working in New York, Connecticut and the United Kingdom. Mr. Meyer graduated cum laude and Phi Beta Kappa with a Bachelor of Arts degree from Cornell University. He earned his Juris Doctor degree from Villanova University School of Law.
Dr. Mitch Nelles is the Chief Operating Officer for XDx. He has more than 20 years of management and research and development experience in a variety of in vitro diagnostic (IVD) technology and business areas. Dr. Nelles joined XDx from bioMerieux Inc. where he was Vice President of North America Research and Development and responsible for product development and project management for the bacteriology, molecular diagnostics, immunodiagnostics and hemostasis business franchises. Prior to his work at bioMerieux, Dr. Nelles served as the Vice President of R&D at TriPath Oncology (TriPath Imaging) where he led the efforts to develop molecular based products for the diagnosis and prognosis of breast and cervical cancer. Earlier in his career, Dr. Nelles held a variety of technical and managerial positions of increasing responsibility, including Vice President, Transfusion Medicine and Immunodiagnostic Assay R&D at Ortho Clinical Diagnostics (Johnson and Johnson) where he led the worldwide research and development activities in support of the blood screening, blood typing, immunodiagnostic and RhoGAM business franchises. Dr. Nelles received his bachelor’s degree from Rutgers College in biological sciences, his Ph.D. in immunology/biomedical sciences from the University of Texas, Health Sciences Center at Dallas (UTHSCD)/Southwestern Medical School, and completed postdoctoral training in immune regulation at Brandeis University.